Contineum Therapeutics, Inc. (CTNM) Income Statement
CTNM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCTNM revenue and net income
CTNM profit margins
CTNM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CTNM quarterly EPS vs estimates
Contineum Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: October 29, 2026 (estimate $-0.45).
CTNM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $50.0M | $0 | $0 |
| Cost of revenue | $323,000 | $258,000 | $195,000 | $329,000 | — |
| Gross profit | −$323,000 | −$258,000 | $50.0M | −$329,000 | — |
| Research & development | $51.5M | $38.2M | $27.6M | $16.9M | $22.4M |
| Sales, general & admin | $16.5M | $12.5M | $6.5M | $5.8M | $6.3M |
| Total operating expenses | $68.1M | $50.6M | $66.1M | $22.7M | $28.6M |
| Operating income | −$68.1M | −$50.9M | −$16.1M | −$22.7M | −$28.6M |
| Interest income | $8.2M | $8.9M | $4.6M | $761,000 | $77,000 |
| Interest expense | — | $0 | $208,000 | $388,000 | $332,000 |
| Income before taxes | −$60.0M | −$42.3M | $23.2M | −$24.3M | −$29.0M |
| Income taxes | — | — | $450,000 | — | $241,000 |
| Net income | −$60.0M | −$42.3M | $22.7M | −$24.3M | −$29.0M |
| EBITDA | −$67.7M | −$42.0M | $23.6M | −$23.5M | −$28.3M |
| EPS (diluted) | −$2.18 | −$4.90 | −$1.44 | −$0.97 | — |
| Gross margin | — | — | 100.0% | — | — |
| Operating margin | — | — | −32.2% | — | — |
| Net margin | — | — | 45.4% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $242,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $83,000 | $85,000 | $81,000 | $79,000 | — | $121,000 | — | $60,000 | $61,000 | $37,000 | — |
| Gross profit | — | −$83,000 | −$85,000 | −$81,000 | −$79,000 | — | $121,000 | — | −$60,000 | −$61,000 | −$37,000 | — |
| Research & development | $12.7M | $11.6M | $12.8M | $11.0M | $14.1M | $13.7M | $13.0M | $9.7M | $7.9M | $7.8M | $8.0M | $6.5M |
| Sales, general & admin | $4.7M | $5.3M | $4.4M | $3.9M | $3.8M | $4.4M | $4.0M | $3.2M | $3.1M | $2.2M | $1.7M | $1.6M |
| Total operating expenses | $17.4M | $16.9M | $17.1M | $14.9M | $17.9M | $18.1M | −$84.7M | $13.0M | $10.9M | $9.9M | $9.7M | $8.1M |
| Operating income | −$17.4M | −$16.9M | −$17.1M | −$14.9M | −$17.9M | −$18.1M | $84.7M | −$13.0M | −$10.9M | −$9.9M | −$9.7M | −$8.1M |
| Interest income | $2.3M | $2.5M | $2.0M | $2.0M | $2.0M | $2.2M | $2.5M | $2.7M | $2.0M | $1.6M | $1.8M | $1.7M |
| Interest expense | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$15.2M | −$14.5M | −$15.2M | −$12.8M | −$16.0M | −$16.0M | −$14.6M | −$10.3M | −$9.0M | −$8.4M | −$7.9M | −$6.4M |
| Income taxes | — | — | — | — | — | — | — | — | — | — | −$161,000 | −$118,000 |
| Net income | −$15.2M | −$14.5M | −$15.2M | −$12.8M | −$16.0M | −$16.0M | −$14.6M | −$10.3M | −$9.0M | −$8.4M | −$7.8M | −$6.3M |
| EBITDA | −$17.3M | −$16.8M | −$17.0M | −$14.9M | −$17.8M | −$18.0M | −$14.5M | −$10.2M | −$8.9M | −$8.4M | −$7.9M | −$6.3M |
| EPS (diluted) | −$0.40 | −$0.39 | −$0.49 | −$0.45 | −$0.62 | −$0.62 | −$0.56 | −$0.40 | −$0.39 | −$3.55 | −$1.44 | — |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | 35,016.9% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −6,018.6% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CTNM's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CTNM financial results
Contineum Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $60.0 million. Diluted earnings per share came to −$2.18.
See the CTNM stock overview for the latest quote and news, or the CTNM chart for price history and technical indicators.
CTNM income statement FAQ
Does Contineum Therapeutics have revenue?
Contineum Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Contineum Therapeutics profitable?
No. Contineum Therapeutics reported a net loss of $60.0 million in fiscal 2025.
How much does Contineum Therapeutics spend on research and development?
Contineum Therapeutics spent $51.5 million on research and development in fiscal 2025.
What are Contineum Therapeutics's earnings per share?
Contineum Therapeutics earned $-2.18 per diluted share in fiscal 2025, compared with $-4.90 a year earlier.
When will Contineum Therapeutics report its next earnings?
Contineum Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes.
When does Contineum Therapeutics's fiscal year end?
Contineum Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.